Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion ...

The Company has placed increased emphasis on its pharmacy gift card program to address the growing critical need for improved preventive care and affordable access to newer treatment options. By ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Roller-coaster healthcare stock Hims & Hers Health ( HIMS 5.26%), whose stock got devastated last week by worries that it ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...